Fibroscan Compared to FIB-4, APRI, and AST/ALT Ratio for Assessment of Liver Fibrosis in Saudi Patients With Nonalcoholic Fatty Liver Disease
Conclusions: The data showed that more than one-third of the cohort exhibited advanced fibrosis, demonstrating the need for the early diagnosis and treatment of NAFLD. The use of Fibroscan with other serum markers has been shown to be helpful for the diagnosis of severe fibrosis.
Source: Hepatitis Monthly - Category: Infectious Diseases Source Type: research
More News: Cancer & Oncology | Carcinoma | Cirrhosis | Diabetes | Endocrinology | Fatty Liver Disease (FLD) | Hepatitis | Hepatocellular Carcinoma | Infectious Diseases | Liver | Liver Cancer | Liver Disease | Metabolic Syndrome | Middle East Health | Non-alcoholic Fatty Liver Diseases (NAFLD) | Study | Urology & Nephrology